Melbourne, Australia: Starpharma (ASX: SPL; OCTQX: SPHRY) today released its Appendix 4C - Quarterly Cashflow report for the period ended 31 December 2011.

The cash balance at 31 December 2011 was $49m, which includes proceeds of $35m (before costs) from the successful capital raising conducted in November 2011.  Total operating and investing cash outflow for the quarter was $1.8m.

These funds are being applied to accelerating and completing both VivaGel^® Bacterial Vaginosis Phase 3 programs (Treatment, and Prevention of Recurrence) supporting an NDA filing and commercial licence, as well as advancing the Company’s drug delivery and agrochemical programs.

Read More